Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A human monoclonal antibody designed for the treatment of cancer of the head and neck.

Etymologies

Sorry, no etymologies found.

Support

Help support Wordnik (and make this page ad-free) by adopting the word zalutumumab.

Examples

  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat Ishaq Siddiqi 2010

  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat Ishaq Siddiqi 2010

  • Genmab shares slumped 20.4% in Copenhagen after the Danish drug maker said that top-line results from a zalutumumab Phase III study in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who failed standard platinum-based chemotherapy didn't meet its primary endpoint of demonstrating a statistically significant difference in overall survival.

    European Stocks Finish Flat Ishaq Siddiqi 2010

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...

    THE MEDICAL NEWS Editors 2010

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...

    THE MEDICAL NEWS Editors 2010

  • Genmab A/S has announced it has initiated a Phase II study of HuMax-EGFr (zalutumumab) in combinatio ...

    THE MEDICAL NEWS Editors 2010

  • In March, we announced top-line results from a zalutumumab Phase III study in refractory head and neck chemotherapy.

    THE MEDICAL NEWS 2010

  • Patients in the study will be randomized into two treatment groups: zalutumumab in combination with best supportive care or best supportive care alone.

    News 2009

  • COPENHAGEN, Denmark, Jan. 5, 2009 (GLOBE NEWSWIRE) -- Genmab A / S (OMX: GEN) announced today that the interim survival analysis of the Phase III pivotal study investigating zalutumumab

    News 2009

  • The objective of the study is to evaluate the efficacy of zalutumumab incombination with best supportive care as compared to best supportive care alone in terms of overall survival.

    News 2009

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.